Innovative Molecules
Innovative Molecules GmbH is a German biotech company dedicated to developing next-generation treatments for herpes simplex-induced diseases. Founded in 2016, the company focuses on discovery, development, and commercialization of novel agents, with a strong expertise in herpes-mediated diseases. Their flagship product, IM-250, is a potent, second-generation helicase-primase inhibitor targeting HSV-1 and HSV-2, with the potential to change the treatment landscape by reducing or eradicating the viral reservoir and decreasing recurrences.
Industries
Nr. of Employees
small (1-50)
Innovative Molecules
Lipowskystr. 10, 81373 Munich, Germany
Patents
Products
Oral selective helicase-primase inhibitor (antiviral small molecule)
An orally available small-molecule inhibitor designed to bind the viral helicase-primase complex, block viral DNA replication, reduce viral load and shedding, and reduce recurrence frequency in herpes simplex infection models.
Oral selective helicase-primase inhibitor (antiviral small molecule)
An orally available small-molecule inhibitor designed to bind the viral helicase-primase complex, block viral DNA replication, reduce viral load and shedding, and reduce recurrence frequency in herpes simplex infection models.
Services
Design and execution of preclinical efficacy, pharmacokinetic, tissue distribution and safety studies in models relevant to herpes simplex virus infection and latency.
Conduct of Phase I and Phase 1b/2a clinical studies including safety, tolerability and pharmacokinetic assessments to progress antiviral candidates into later-stage development.
Design and execution of preclinical efficacy, pharmacokinetic, tissue distribution and safety studies in models relevant to herpes simplex virus infection and latency.
Conduct of Phase I and Phase 1b/2a clinical studies including safety, tolerability and pharmacokinetic assessments to progress antiviral candidates into later-stage development.
Expertise Areas
- Clinical trial management (early-phase)
- Antiviral small-molecule drug discovery
- Preclinical translational research (latency/reactivation models)
- Pharmacokinetics and tissue-distribution (neuronal/CNS targeting)
Key Technologies
- Helicase-primase inhibition (antiviral mechanism)
- Oral small-molecule therapeutics
- In vivo latency/reactivation animal models
- Pharmacokinetic and tissue-distribution studies
News & Updates
Innovative Molecules GmbH announced the completion of enrollment in the Phase 1b clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor targeting herpes simplex virus (HSV). The study assesses safety, efficacy, and pharmacokinetics of once-weekly oral dosing in patients with recurrent genital herpes.
The first subjects have received IM-250 in a Phase 1 clinical trial conducted at the University Clinic Heidelberg in Germany. The trial evaluates safety, tolerability, and pharmacokinetics of IM-250 in healthy volunteers.
Preclinical data shows IM-250 affects acute and chronic neural HSV infections in animal models, reducing viral load, shedding, and recurrences, with a potential to treat neurotrophic herpes simplex.
The company announced a €20 million Series A funding led by LSP to advance IM-250 to Phase II, aiming to establish a new treatment standard for herpes simplex diseases.
Innovative Molecules GmbH announced the completion of enrollment in the Phase 1b clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor targeting herpes simplex virus (HSV). The study assesses safety, efficacy, and pharmacokinetics of once-weekly oral dosing in patients with recurrent genital herpes.
The first subjects have received IM-250 in a Phase 1 clinical trial conducted at the University Clinic Heidelberg in Germany. The trial evaluates safety, tolerability, and pharmacokinetics of IM-250 in healthy volunteers.
Preclinical data shows IM-250 affects acute and chronic neural HSV infections in animal models, reducing viral load, shedding, and recurrences, with a potential to treat neurotrophic herpes simplex.
The company announced a €20 million Series A funding led by LSP to advance IM-250 to Phase II, aiming to establish a new treatment standard for herpes simplex diseases.